Article
HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy.
The Journal of antimicrobial chemotherapy - 1 Sept 2026
Abdullahi Adam, Osawe Sophia, Wisso Haruna, Edun Martin, Adebisi Grace, Arachie Judith, Ude Chinedu, Onyemata James, Alhaji Suleiman Yusuf, Bara Jibrin Yusuf, Abimiku Alash'le, Kemp Steven A, Gupta Ravindra K
Abstract excerpt
BACKGROUND: Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid variation alongside emerging integrase resistance is increasingly important. Whether DTG resistance...
Read the complete abstract on PubMedTopics
- Humans
- HIV-1
- Drug Resistance, Viral
- HIV Infections
- HIV Integrase Inhibitors